Press Releases

August 5, 2019 at 7:00 AM EDT
Altimmune to Announce Second Quarter 2019 Financial Results on August 14
GAITHERSBURG, Md. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 2019
July 15, 2019 at 7:00 AM EDT
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
GAITHERSBURG, Md. , July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc. , including the product candidate ALT-801, a potent GLP-1/Glucagon receptor
June 12, 2019 at 8:00 AM EDT
Altimmune Appoints Will Brown as Chief Financial Officer
GAITHERSBURG, Md. , June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018 .
June 10, 2019 at 8:00 AM EDT
Altimmune Announces Successful Pre-IND Meeting with FDA
Meeting on HepTcell Phase 2 program for treatment of chronic hepatitis B (HBV) GAITHERSBURG, Md. , June 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting
May 8, 2019 at 8:00 AM EDT
Altimmune to Announce First Quarter 2019 Financial Results on May 15
GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2019 before the market open and host a conference call on Wednesday, May 15,
Displaying 1 - 10 of 17

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe